RxDoctor Payments Data

Lawrence Ang, MD

Interventional Cardiology · San Diego, CANPI 1851529879

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (32.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Opsens Inc. at 51.8% of the total. Reporting peaked in 2019 at $2,580 and has fallen 91.1% since, to $229 in 2025. That places this record below the midpoint for interventional cardiology clinicians in CA, where the typical reported total is $8,581.

$7,753in general payments, 2019–2025

Across 65 payments — averaging $119.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Opsens Inc.$4K
  • Edwards Lifesciences$2K
  • Abbott$408
  • Shockwave Medical, Inc$354
  • ZOLL Circulation Inc$261
  • Boston Scientific$159
  • plus $759 from 15 others
$376,055in research payments, 2019–2025

Across 48 payments — averaging $7834.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$252K
  • Chiesi USA, Inc.$91K
  • Boston Scientific$33K
  • Abiomed$150

What the payments were for

  • Consulting fees$1,50019%
  • Speaking & faculty fees$2,50032%
  • Travel & lodging$1,37218%
  • Food & beverage$2,33930%
  • Education$250%
  • Entertainment$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,753 in reported general payments places this provider in the 45th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$150,422
Medicare patients
243
Services billed
816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor12$5,381
ClopidogrelClopidogrel Bisulfate21$249

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →